Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Nova Southeastern University has 3 pending office actions distributed across the Biotechnology & Pharmaceuticals technology area. These actions are being reviewed by 3 distinct examiners, which suggests a variety of individual perspectives on the university's patent applications. The workload is spread across 2 distinct art units, indicating that the technology being patented spans multiple specialized divisions.
The busiest examiner for the university is HERNANDEZ, JACKSON J, who is currently managing 1 busiest examiner pending action. This means that the 3 pending office actions are assigned to different examiners, as the busiest examiner only accounts for a single action. Navigating 2 distinct art units requires the university to adhere to the specific examination guidelines of each group. The presence of distinct examiners for the pending actions highlights a lack of examiner concentration, requiring a tailored strategy for each individual case. The Biotechnology & Pharmaceuticals technology area further defines the specialized nature of the workload.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HERNANDEZ, JACKSON J | 1 | 51.4% | +45.0% |
| BRISTOL, LYNN ANNE | 1 | 63.4% | +39.8% |
| NIEBAUER, RONALD T | 1 | 40.8% | +34.0% |
| VALLE, ERNESTO | 1 | 65.8% | +32.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17776273 | METHODS AND COMPOSITIONS FOR TREATMENT OF SOLID TUMORS USING F16 ISOINDOLE SMALL MOLECULES | VALLE, ERNESTO | 26d |
| 18284894 | CLADE C HIV-1 ENVELOPE (ENV) TRIMER IMMUNOGENS, COMPOSITIONS INCLUDING THE CLADE C HIV-1 ENVELOPE (ENV) TRIMER IMMUNOGENS, AND USES THEREOF | BRISTOL, LYNN ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17776273 | METHODS AND COMPOSITIONS FOR TREATMENT OF SOLID TUMORS USING F16 ISOINDOLE SMALL MOLECULES | VALLE, ERNESTO | 26d |
| 18843817 | METHOD FOR TREATING RHEUMATOID ARTHRITIS (RA) USING AN ENZYME-AND SUBSTRATE SELECTIVE EXOSITE INHIBITOR OF A DISINTEGRIN AND METALLOPROTEASE 10 (ADAM10) | HERNANDEZ, JACKSON J | — |
| 18284894 | CLADE C HIV-1 ENVELOPE (ENV) TRIMER IMMUNOGENS, COMPOSITIONS INCLUDING THE CLADE C HIV-1 ENVELOPE (ENV) TRIMER IMMUNOGENS, AND USES THEREOF | BRISTOL, LYNN ANNE | — |
| 17944574 | MELANOCORTIN LIGANDS AND METHODS OF USE THEREOF | NIEBAUER, RONALD T | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| 1658 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18843817 | METHOD FOR TREATING RHEUMATOID ARTHRITIS (RA) USING AN ENZYME-AND SUBSTRATE SELECTIVE EXOSITE INHIBITOR OF A DISINTEGRIN AND METALLOPROTEASE 10 (ADAM10) | HERNANDEZ, JACKSON J | — | §103 | Non-Final OA | — | Pending | Sep 04, 2024 |
| 18284894 | CLADE C HIV-1 ENVELOPE (ENV) TRIMER IMMUNOGENS, COMPOSITIONS INCLUDING THE CLADE C HIV-1 ENVELOPE (ENV) TRIMER IMMUNOGENS, AND USES THEREOF | BRISTOL, LYNN ANNE | 1643 | §103§112 | Non-Final OA | — | Pending | Sep 29, 2023 |
| 17944574 | MELANOCORTIN LIGANDS AND METHODS OF USE THEREOF | NIEBAUER, RONALD T | 1658 | §102DP | Final Rejection | — | Pending | Sep 14, 2022 |
| 17776273 | METHODS AND COMPOSITIONS FOR TREATMENT OF SOLID TUMORS USING F16 ISOINDOLE SMALL MOLECULES | VALLE, ERNESTO | 1623 | §102§103 | Final Rejection | 26d | Pending | May 12, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial